Linezolid, Levofloxacin, and Vancomycin Against Vancomycin-Tolerant and Fluoroquinolone-Resistant Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model

Pharmacotherapy

Volumn 23, Issue 12 I, 2003, Pages 1531-1537

  Cha, Raymond ^a   Akins, Ronda L ^c   Rybak, Michael J ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

In vitro model; Linezolid; Pharmacodynamic; Streptococcus pneumoniae; Tolerance; Vancomycin tolerant Streptococcus pneumoniae

Indexed keywords

LEVOFLOXACIN; LINEZOLID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MODEL; NONHUMAN; PHARMACODYNAMICS; STREPTOCOCCUS PNEUMONIAE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; OXAZOLIDINONES; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN;

EID: 0344874267     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.15.1531.31964     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention. Geographic variation in penicillin resistance in Streptococcus pneumoniae: selected sites, United States, 1997. MMWR Morb Mortal Wkly Rep 1999;48:656-61.
2. Centers for Disease Control and Prevention. Defining the public health impact of drug-resistant Streptococcus pneumoniae: report of a working group. MMWR Morb Mortal Wkly Rep 1999;45:RR-1.
3. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001;45:1721-9.
4. Pfaller MA, Jones RN, Doern GV, Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998;42:1762-70.
5. Diekema DJ, Brueggemann AB, Doern GV. Antimicrobial-drug use and changes in resistance in Streptococcus pneumoniae. Emerg Infect Dis 2000;6:552-6.
6. Chen DK, McGeer A, De Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-9.
7. Ho PL, Que TL, Tsang DNC, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999;43:1310-13.
8. Linares J, Campa AG, Pallares R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999;20:1546-8.
9. Goldstein EJC, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin Infect Dis 2002;35:1505-11.
10. Novak R, Henriques B, Charpentier E, Normark S, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 1999;399:590-3.
11. McCullers JA, English BK, Novak R. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 2000;181:369-73.
12. Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 1998;18:456-62.
13. Swaney SM, Aoki HA, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42:3251-5.
14. Barry, AL, Fuchs PC, Brown SD. In vitro activities of five fluoroquinolone compounds against strains of Streptococcus pneumoniae with resistance to other antimicrobial agents. Antimicrob Agents Chemother 1996;40:2431-3.
15. Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis 1998;27:33-9.
16. Coyle EA, Kaatz GW, Rybak MJ. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:1654-9.
17. National Committee for Clinical Laboratory Standards. Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. NCCLS document M7-A4. Villanova, PA: National Committee for Clinical Laboratory Standards, 1997.
18. Handwerger S, Tomasz A. Antibiotic tolerance among clinical isolates of bacteria. Rev Infect Dis 1985;7:368-86.
19. Hershberger E, Rybak MJ. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. Antimicrob Agents Chemother 2000;44:598-601.
20. Zabinski RA, Larsson AJ, Walker KJ, Gilliland SS, Rotschafer JC. Elimination of quinolone antibiotic carryover through use of antibiotic-removal beads. Antimicrob Agents Chemother 1993;37:77-9.
21. May J, Shannon K, King A, French G. Glycopeptide tolerance in Staphylococcus aureus. J Antimicrob Chemother 1998;42:189-97.
22. Normark BH, Novak R, Ortqvist A, Kallenius G, Tuomanen E, Normark S. Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin. Clin Infect Dis 2001;32:552-8.
23. Cha R, Rybak MJ. Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003;47:1984-7.